Despite these limitations, we specifically evaluated the relevance of KIT mutations to CBF-AML, performing subgroup analysis according to CBF abnormalities and patient ethnicity, thereby rendering this meta-analysis more powerful than any individual study. The gene discussed is KIT; the disease is acute myeloid leukemia.